Buy-Side US Biotechnology Equity Research Analyst

The RoleThe successful candidate will contribute significantly to alpha generation of their long-only equity strategies by supporting the identification of the best investment opportunities, as well as gain exposure to senior corporate executives, key opinion leaders, and other high-profile industry experts. Depending on the candidate's level of experience, a successful candidate can initially expect to perform support in the analysis and modeling of prospective companies; candidates with more experience will have their own lead coverage of a portion of the biotech universe.The role is based in New York, USA and reports to Wendy Lam, Deputy Head Investment Management and Head of US Research BB Biotech. The role will be employed at Bellevue Research Inc., a fully owned subsidiary of Bellevue Asset Management AG.Main ResponsibilitiesGenerate stock ideas by assessing company management, company strategy, clinical data, market potential and competitive landscape.Conduct deep dive technology assessment.Prepare, conduct and summarize company meetings.Create and update financial company models including valuation.Write thorough research reports and propose investments to the investment team.Ongoing monitoring of research coverage including news updates, earnings reports, companyindustry conference calls and other data sources.Attend scientificmedical and investor conferences.Candidate ProfileTechnical qualifications & competencies:Bachelor's degree or higher in life sciences (PhD or MD preferred but not required).At least 2-5 years of experience as a buy-side equity research analyst, preferably in the pharmabiotech healthcare space. Experience on the sell-side, in VC, Private Equity, and Investment Banking are also welcome.Strong analytical skills and the ability to conduct deep fundamental analysis.Strong financial modeling skills a plus.Strong written and verbal communication skills.Proficient in Microsoft office including advanced Excel skills, Bloomberg skills are a plus.About BB BiotechBB Biotech is one of Europe's largest biotechnology-focused funds. It invests in established large-cap biotechnology companies as well as fast-growing earlier-stage smid-cap companies with innovative, best-in-class drugs. The long-only investment portfolio consists of 20-35 holdings in public and private biotech companies. BB Biotech's team consists of investment professionals with biomedical backgrounds and extensive industry experience. The team employs an thorough due diligence approach to assess individual companies and their products, pipelines, competitive landscapes, management quality, and commercial prospects.For more information, please visit: look forward to receiving your full application to

Created: 2025-02-22